Company ProfilePremium

CKD Bio Corp.

Company Profile Analysis

Ticker: 063160.KS주식회사 종근당바이오

ESOMAR 23 Corporate BadgeISO Certifications Badge
CKD Bio Corp. - Company showcase

Year Founded & Workforce

2001

530 Employees

CKD Bio Corp. logo

CKD Bio Corp. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

CKD Bio Corp. Overview

CKD Bio is the fermentation-API arm of the Chong Kun Dang group, one of Korea's largest pharmaceutical groups. It was carved out of Chong Kun Dang in 2001 and inherited a fermentation heritage dating to the 1960s, including Korea's first US FDA approval (chloramphenicol, 1968).

Its core is a B2B, export-oriented portfolio of fermentation-derived antibiotics, β-lactamase inhibitors, immunosuppressants and antidiabetic APIs, made at a large Ansan plant approved by the FDA, AIFA, PMDA and TGA. Two newer businesses sit on top of this base:

  • a probiotics raw-material and CDMO business, historically anchored by supply to sister company Chong Kun Dang Health's Lactofit brand;

  • a botulinum toxin franchise, Tyemvers (CU-20101 / CKDB-501A), approved in Korea in March 2025, filed in China in August 2026, and in US neuropsychiatric development via partner Healis.

The company is small (FY2025 revenue KRW 160.1B), thinly capitalised (market capitalisation about KRW 74B) and leveraged (net debt about KRW 141B). It sits in a margin squeeze between Indian and Chinese API price competition and an early-stage toxin ramp.


Company's own description. The company describes itself as a developer and producer of high value-added products built on internationally competitive fermentation, synthesis and biotechnology capabilities, backed by continuous R&D (company "CKD BiO" overview page). It describes its Ansan plant in the Banwol industrial complex (51,473 m² site) as supplying the world with antibiotics, β-lactamase inhibitors, antidiabetics and immunosuppressants. The FY2025 annual report summary on FinancialFilings characterises it as a pharmaceutical company specialising in fermentation and chemical synthesis that also produces next-generation probiotics using patented technology.

What it actually does. CKD Bio runs four economic activities:

  1. Fermentation and semi-synthetic APIs and intermediates (core; about 83–86% of revenue). Bulk drug substances sold to generic and originator manufacturers worldwide. Key molecules include:

    • potassium clavulanate (β-lactamase inhibitor);

    • rifampicin and rifamycin sodium (anti-tuberculosis);

    • teicoplanin (glycopeptide antibiotic);

    • demeclocycline HCl (DMCT);

    • acarbose (antidiabetic);

    • cyclosporine, tacrolimus and everolimus (immunosuppressants);

    • diquafosol sodium (dry-eye). The company also sells API trading, contract research and contract manufacturing services (product pages, 2026). In 1Q2025, APIs were 85.9% of revenue (KRW 36.5B), and antibiotics alone were 62.1% (KRW 26.4B) (Nate/Bio report, Apr-2026).

  2. Probiotics (about 13–14% of revenue). Production of probiotic "raw powder" (원말) and finished products. The catalogue lists 25 strains/items, including S. thermophilus, L. bulgaricus, L. rhamnosus, L. reuteri, B. breve and B. longum, at concentrations up to 5×10¹¹ CFU/g (product page). A major historic customer is related party Chong Kun Dang Health (Lactofit). The company also offers microbiome CDMO services.

  3. Botulinum toxin type A (about 2% of revenue in 2025–1H2026). Tyemvers 100U, launched in Korea on 21–22 July 2025, with a 200U presentation launched in August 2026. Out-licensing economics come from Cutia Therapeutics (Greater China) and a supply arrangement with Healis Therapeutics (US neuropsychiatry).

  4. Contract manufacturing / CDMO. Offered for APIs, intermediates and microbiome products using cGMP fermentation and synthesis assets (company home page).

Revenue model. Revenue is predominantly product sales:

  • B2B bulk API shipments, priced per kilogram under supply contracts and spot orders;

  • B2B probiotic powders;

  • B2C/B2B toxin vials sold to Korean clinics through the company's own sales organisation.

There is small licence and milestone income from toxin partners. For example, the FY2022 toxin-segment revenue of KRW 6.0B is consistent with the Cutia upfront payment plus the China IND milestone (US$2.0M + US$2.5M). There is no subscription revenue.

Value-chain position. Upstream manufacturer of drug substances, sitting between raw-material and nutrient suppliers and finished-dosage formulators. In toxin, the company is vertically integrated from strain to vial.

Customer types and end-markets.

  • Generic and originator drug makers in the US, EU, Japan, emerging markets and Korea. Exports were 79.0% of revenue in 1Q2025 (Medigate, Jun-2025).

  • Health-functional-food brand owners.

  • Korean dermatology and plastic-surgery clinics (toxin).

  • Licensees (Cutia, Healis).

Independent characterisation. CKD Bio is a sub-scale, legacy fermentation-API exporter trying to buy a growth option (toxin) with a balance sheet that has little room for error. The API base provides volume and GMP credibility but is structurally exposed to Indian and Chinese pricing (Kormedi, Apr-2026). Group affiliation (Chong Kun Dang Holdings 39%) provides financing comfort and related-party demand (probiotics), but also governance overlap. The toxin business is differentiated on paper:

  • human-serum-albumin-free (vegan) formulation;

  • GenBank-registered strain of German/European origin;

  • first halal certificate (BPJPH) for a botulinum toxin.

However, it entered as Korea's sixth domestic toxin into a crowded, price-competitive market.

Strategy

Stated strategic themes (company materials and press releases, 2025–2026):

Global probiotics and pharma leadership: The English website states an ambition to become a global leader in probiotics and pharmaceuticals through world-class technology and continuous R&D.

Toxin globalisation on a "clean label" platform: The company positions Tyemvers on strain-origin transparency, an HSA-free vegan process and halal status. It targets Indonesia, the Middle East and Malaysia, and pursues China and the US through partners (press releases, Jul-2025 and Jun-2026). CEO Park framed the 1-year anniversary as a platform to expand domestically and globally (FN News, Jul-2026).

API cost leadership and portfolio refresh: Pipeline additions include diquafosol (dry-eye), an antiviral, an anti-ulcer agent (process validation complete) and several next-generation antibiotics (R&D pipeline page).

Strategic initiatives in the last 24 months (Oct-2024 to Oct-2026):

Medium-term financial targets / guidance: n/d. The company does not publish formal guidance. The only forward-looking commercial target found is the China launch in 2H2027.

Sustainability commitments: ISO 14001 (2022), ISO 45001 (2023) and ISO 37001 anti-bribery (2021) certifications; numeric targets n/d.

Products & Services

API Division — fermentation and synthetic APIs

ProductClass / applicationKey regulatory credentialsFlagship notesSource
Potassium clavulanateβ-lactamase inhibitor, paired with amoxicillinEDQM CEP (2005); US FDA GMP (2007, 2012); AIFA GMP (2008, 2013)"World-class Product" (2004); historically the flagship exportCompany history
RifampicinAnti-tuberculosisUS FDA (1985, 2001, 2007, 2012); AIFA (2013); WHO GMP (2013)Fermentation production since 1980Company history
Rifamycin sodiumAntibiotic / rifampicin precursorEDQM CEP (2011); AIFA (2013)—Company history
TeicoplaninGlycopeptide antibiotic (MRSA)EDQM CEP (2011); AIFA (2008, 2013)—Company history
Demeclocycline HCl (DMCT)Tetracycline-class antibioticUS FDA (1991, 2007, 2012)"World-class Product" (2014)Company history
AcarboseAntidiabetic (α-glucosidase inhibitor)EDQM CEP (2008); PMDA (2008); AIFA (2013)"World-class Product" (2010)Company history
CyclosporineImmunosuppressantEDQM CEP (2009); AIFA (2008, 2013); ANVISA (2012)"Good Technology of Korea" (1995)Company history
TacrolimusImmunosuppressant—The company highlights a proprietary purification technology as a next-generation core productCompany overview page
EverolimusImmunosuppressant / anti-cancerUS DMF; EU DMF under development; in-house and EP specifications; 100 g aluminium-can pack—Product page
Diquafosol sodiumDry-eye treatmentJ-DMF under development; 10 kg fibre-drum packCorresponds to pipeline item CKDB-17 (commercialised)Product page; pipeline
Antiviral API (CKDB-103)Antiviral—Pipeline status: production/launch completeR&D pipeline page
Other listed classes (obesity/anti-cancer API; additional antibiotics)Per website filter categories—Individual names not retrievableProduct page

The company website lists 14 API products across these categories: antibiotics, β-lactamase inhibitors, immunosuppressants, immunosuppressant/anti-cancer, obesity/anti-cancer, dry-eye, antivirals, antidiabetics and anti-tuberculosis. The table below lists every product name confirmed from the company website and history. The remaining website items are not individually retrievable.

Target customers: global generic and originator formulators.

Pricing model: per-kg supply contracts; prices n/d.

Services: API trading, contract research and contract manufacturing (website service tabs).

Probiotics Division

ItemDescriptionSource
Probiotic raw materials (25 items)Includes Streptococcus thermophilus (4×10¹¹ and 1×10¹¹ CFU/g), Lactobacillus bulgaricus, L. fermentum, L. helveticus, L. salivarius, L. reuteri (1×10¹¹ CFU/g), L. gasseri (1×10¹⁰), L. rhamnosus (5×10¹¹ and 1×10¹¹), Bifidobacterium breve (3×10¹¹ and 1×10¹¹), B. longum (1×10¹¹)Probiotics product page
Lactofit raw powder supplyCore raw powder supplied to Chong Kun Dang Health's Lactofit brand (related party). The company was described as Lactofit's key raw-material supplier in 2019.DailyPharm (Aug-2019; 2020 article)
Finished probioticsEntry into finished-product exports; companion-animal probiotics also targetedDailyPharm (company vision article)
Microbiome CDMOContract development and manufacturing for microbiome productsCompany website menu
Patented technologyProcess technology to improve acid and bile tolerance and gut adhesionNICE D&B (Jul-2024)
Functional ingredient pipelineCKDB-305 (triglyceride improvement, launched); CKDB-315 (respiratory health, human study complete); CKDB-322 (body fat, human study ongoing); CKDB-314 (glycaemic control, R&D)R&D pipeline page

Probiotics revenue history: KRW 2.7B (2017), KRW 5.4B (2018) (DailyPharm, 2019); KRW 15.4B (FY2020), KRW 34.0B (FY2021), KRW 25.0B (FY2022) (S&P Global); KRW 18.2B (9M2024) (Medipana).

Botulinum Toxin Division — Tyemvers (TYEMVERS®; CU-20101; CKDB-501A)

AttributeDetailSource
MoleculeClostridium botulinum toxin type A, 100U and 200UMFDS approval (Mar-2025); 200U launch (Aug-2026)
StrainExclusively licensed from a European (German) research institute in Jun-2019; registered in NCBI GenBank, which reduces strain-origin litigation riskDailyPharm (Jan-2022); BioSpectator (Jul-2025)
FormulationHuman serum albumin-free, non-animal excipients, vegan process; contains L-histidineHankyung (Apr-2025); FN News (Jul-2026)
Indication (Korea)Moderate-to-severe glabellar lines; approved 31-Mar-2025DailyPharm (Apr-2025)
Korean Phase 3300 patients; randomised, double-blind, active-controlled, multi-centre; non-inferior to onabotulinumtoxinA (Botox); published in Journal of Cosmetic Dermatology (2025)BioSpectator (Jul-2025)
China Phase 3554 patients; non-inferior to Botox; no treatment-related serious adverse events; repeat-dose profile similar to single doseBizwatch (Aug-2026)
HalalFirst botulinum toxin certified by Indonesia's BPJPH (May-2025)Smart Today (May-2025)
LaunchKorea 21/22-Jul-2025 (6th domestic Korean toxin); 200U launch Aug-2026Medigate (Jul-2025); Toyo Economy (Jul-2025)
CapacityOsong plant: 6M vials/yr, planned expansion to 16M vials/yrDailyPharm (Jan-2022)
Pricing——
Therapeutic pipelineCKDB-501A therapeutic indications in clinical development (company pipeline); US Phase 1 in major depressive disorder via Healis (IND cleared Jul-2026)Pipeline page; DailyPharm (Jul-2026)
Revenue scaleKRW 0.8B in 1Q2025; about 2% of revenue in 2Q2026Nate (Apr-2026); Butler

Financial Narrative

Income statement (FY2021–FY2025)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

SegmentFY2020FY2021FY2022

API division revenue (KRW Bn)

109.2108.2125.1

Probiotics division revenue (KRW Bn)

15.434.025.0

Botulinum toxin division revenue (KRW Bn)

006.0

Total revenue (KRW Bn)

124.6142.2156.0

API share of revenue (%)

87.676.180.2

Probiotics share of revenue (%)

12.423.916.0

Segment Margins & Growth (%)

SegmentFY2021FY2022

API division YoY growth (%)

-0.915.6

Probiotics division YoY growth (%)

120.3-26.6

Data Point by Period

PeriodData pointSource

FY2023

API group = 83.5% of revenue

NICE D&B technical report (Jul-2024)

9M2024

Probiotics revenue KRW 18.2B; probiotics operating profit KRW 2.3B (the only segment profit disclosure found)

Medipana (Jan-2025)

1Q2025

API KRW 36.5B (85.9%), of which antibiotics KRW 26.4B (62.1%); toxin KRW 0.8B (≈2%)

Nate/Bio report citing DART (Apr-2026)

FY2025

API revenue KRW 113.0B, with overseas share stated as 85% (KRW 110.7B). The two figures are internally inconsistent, since 110.7/113.0 = 98%; treat with caution.

Kormedi (Apr-2026)

FY2025

Product mix: antibiotics 71%, probiotics 13%, immunosuppressants 12%, cardiovascular 4%

Jobkorea financial page (2026)

2Q2026

API 84%, probiotics 14%, botulinum toxin 2%

Butler (2026)

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

142.2156.0160.4171.8160.1

Revenue growth YoY (%)

14.29.72.87.1-6.8

Gross profit (KRW Bn)

13.316.85.035.928.8

Operating income (KRW Bn)

-11.4-14.8-20.211.03.6

Net income (KRW Bn)

-6.6-16.7-24.28.7-2.9

EPS basic = diluted (KRW)

-1,199-3,045-4,4101,586-526

Gross margin (%)

9.410.83.120.918.0

Operating margin (%)

-8.0-9.5-12.66.42.2

Net margin (%)

-4.6-10.7-15.15.1-1.8

R&D expense (KRW Bn)

11.515.417.214.012.6

R&D intensity (% of revenue)

8.19.910.78.17.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis

MetricPeriodValueSource

D&A (KRW Bn)

FY2021 / FY2022 / FY2025

17.0 / 17.9 / 15.7

S&P Global; Valueline (FY2025: depreciation 14.64 + amortisation 1.01)

EBITDA (KRW Bn)

FY2021 / FY2022 / FY2025

5.6 / 3.1 / 18.3

Computed as OI + D&A; FY2025 per Valueline

EBITDA margin (%)

FY2021 / FY2022 / FY2025

3.9 / 2.0 / 11.4

Computed

Pre-tax income (KRW Bn)

FY2021 / FY2022 / FY2025

-13.4 / -18.6 / -3.0

S&P (pre-tax margin × revenue); Valueline

Interest expense (KRW Bn)

FY2021 / FY2022 / FY2025

1.9 / 2.9 / 5.6

S&P Global; Valueline

Dividend per share (KRW)

FY2018 / FY2019 / FY2020 / FY2021

190 / 190 / 200 / 100 (FY2018–19 split-adjusted)

S&P Global

Dividend per share (KRW)

FY2024

≈100 (inferred from KRW 0.54B paid in 1H2025 on 5.49M shares)

Valueline cash-flow data

Dividend per share (KRW)

FY2022, FY2023

——

Dividend per share (KRW)

FY2025

No dividend outflow in 1H2026, consistent with no FY2025 dividend

Valueline

Revenue History

QuarterRevenueOperating incomeNet incomeSource

1Q2024

—3.2—

DailyPharm (Apr-2024)

2Q2024

51.05.04.4

The Fact (Jul-2024)

1Q2025

42.52.10.9

DART preliminary (25-Apr-2025)

2Q2025

41.22.9-0.5

DART preliminary (25-Jul-2025)

3Q2025

34.1-1.5-2.2

DART preliminary (31-Oct-2025)

4Q2025 (implied)

42.3

≈0.1

≈-1.1

FY2025 less 9M2025 (computed)

1Q2026

40.7-1.7-2.0

DART preliminary (24-Apr-2026)

2Q2026

41.1-5.0-5.4

DART preliminary (31-Jul-2026)

1H2026 cumulative

81.8-6.7-7.4

Kormedi (Aug-2026)

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Bn)

298.5312.6293.8284.5299.9

Cash and short-term financial assets (KRW Bn)

3.516.76.31.21.5

Trade receivables (KRW Bn)

29.125.934.031.234.7

Inventory (KRW Bn)

70.478.569.180.596.8

PP&E (KRW Bn)

191.2179.3170.8158.1153.7

Goodwill (KRW Bn)

00000

Intangible assets (KRW Bn)

2.83.86.16.55.6

Short-term borrowings incl. current portion and bonds due within 1 year (KRW Bn)

19.356.375.870.1125.6

Long-term borrowings and bonds (KRW Bn)

89.380.469.459.917.3

Total borrowings (KRW Bn)

108.6136.7145.2130.0142.9

Net debt (KRW Bn)

105.1120.0138.9128.8141.4

Total liabilities (KRW Bn)

137.0164.8170.8153.5172.8

Shareholders' equity (KRW Bn)

161.5147.8123.0131.0127.0

Working capital (KRW Bn)

60.041.913.224.5-15.8

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

-5.9-3.2-7.214.0-4.1

Metric

Period

Value (KRW B)

Source

——

Capex (PP&E purchases)

FY2021 / FY2022 / FY2025

20.5 / 6.2 / 6.8

S&P Global; Valueline

——

Free cash flow (OCF − capex)

FY2021 / FY2022 / FY2025

-26.4 / -9.4 / -10.9

Computed

——

Capex and FCF

FY2023, FY2024

————

Dividends paid

FY2021 / FY2022 / FY2025

1.10 / 0.55 / 0.54

S&P Global; Valueline

——

Share buybacks

FY2021–FY2025

None (no treasury shares)

Butler; Valueline

——

Capex, earlier peak

FY2019 / FY2020

47.3 / 61.7 (Ansan probiotics and Osong toxin plants)

S&P Global

——

Operating cash flow, TTM to 30-Jun-2026

—1.0

Valueline

——

Capex, TTM to 30-Jun-2026

—10.75

Valueline

——

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%; net income / average equity)

-4.0-10.8-17.96.9-2.2

ROA (%; net income / average assets)

-2.3-5.5-8.03.0-1.0

Pre-tax ROIC (%; OI / year-end equity + net debt)

-4.3-5.5-7.74.21.3

Current ratio (x)

2.351.511.131.270.90

Borrowings / equity (x)

0.670.921.180.991.13

Liabilities / equity (%)

84.8111.5138.9117.2136.1

Asset turnover (x)

0.490.510.530.590.55

Days inventory outstanding (days)

199206162216269

Days sales outstanding (days)

7561776679

Days payables outstanding (days)

2822161617

Cash conversion cycle (days)

246245223266331

Financial Analysis — Net debt / EBITDA

RatioPeriodValueNote

Net debt / EBITDA (x)

FY2021 / FY2022 / FY2025

18.8 / 38.7 / 7.7

FY2023–FY2024 EBITDA n/d

Interest coverage, OI / interest (x)

FY2021 / FY2022 / FY2025

-5.9 / -5.0 / 0.64

—

Net debt / EBITDA, TTM to Jun-2026 (x)

—

≈13.8

Net debt KRW 145.8B; EBITDA KRW 10.6B (Valueline TTM)

EBITDA / interest, TTM to Jun-2026 (x)

—

≈1.9

Interest KRW 5.6B

Measure by Period

PeriodMeasureValueSource

1Q2025

Export share of revenue

79.0% (above the 30.6% average for 50 listed Korean pharma companies)

Medigate (Jun-2025)

TTM to Jun-2025

Domestic vs export revenue

Domestic KRW 44.0B; export KRW 115.1B (export ≈72%)

DART line items via Valueline

FY2025

API overseas share

Stated as 85%, i.e.

Kormedi (Apr-2026)

2Q2025

Export mix and toxin share

Exports up YoY, with Korea's API exporters cited as growing on European demand

Medigate (Jun-2025)

2010

Export milestone

US$100M Export Tower award

Company history; NICE D&B

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

23,80023,85022,00020,350

Year-end market cap (KRW Bn)

130.6130.8120.7111.6

Year-end price-to-book (x)

0.881.060.920.88

Performance Measure Details

Performance measureValueBasis / source

Last price

KRW 13,500 (19-Oct-2026)

Valueline

YTD 2026

-33.7%

Computed vs KRW 20,350 at end-2025

≈3-year (vs end-2023)

-43.4%

Computed vs KRW 23,850

1-year

-40.1% (Paasa snapshot) / -49.2% (Investing.com, 29-Jul-2026)

Third-party snapshots

5-year

-67.6%

Paasa snapshot (date n/d)

52-week range

KRW 11,770 – 24,900 (Stockhub, Sep-2026); KRW 12,150 – 27,650 (Investing.com, Jul-2026)

—

Liquidity

3-month average volume ≈52.6K shares

Investing.com (Jul-2026)

Valuation Multiples

MultipleCKD BioBasis

P/E (TTM)

n/m (loss)

TTM EPS ≈ KRW -1,958 (Valueline)

P/B

≈0.62x

BPS KRW 21,795 (30-Jun-2026)

P/S (TTM)

≈0.47x

TTM revenue KRW 158.1B (Jun-2026)

EV (KRW Bn)

≈219.9

Market cap 74.1 + net debt 145.8 (Jun-2026)

EV/Sales (TTM)

≈1.39x

—

EV/EBITDA (TTM)

≈20.8x

TTM EBITDA KRW 10.56B (Valueline)

Capital Markets

ItemStatusSource

Analyst consensus

No current sell-side coverage

Simply Wall St

Historical coverage

Hana Financial (2019–20; BUY, TP KRW 42,100); Daishin (2019–20); Korea IR Council (2022); NICE D&B technical report (2024); iM Securities (2024)

Alphasquare archives

Dividend policy

Historically about KRW 100–200 per share; FY2021 KRW 100; FY2024 ≈KRW 100 (inferred); FY2025 nil (inferred). Dividend yield shown as 0.49% (Stockhub) / 0.69% (Eulerpool) on trailing data.

S&P; Valueline; Stockhub

Buyback authorisations

None; no treasury stock

Butler

Credit ratings (Moody's / S&P / Fitch)

None. No public domestic rating found; bonds of KRW 25.2B (FY2022) and KRW 36.9B (FY2023–FY2024) appear to have been privately placed and were redeemed by 1H2026.

Valueline

Debt maturity profile (30-Jun-2026)

Due within 1 year: KRW 102.0B (short-term borrowings 96.3 + current portion of long-term debt 5.7). Due after 1 year: KRW 44.4B. Detailed ladder n/d.

Valueline (DART half-year report)

Analyst Conclusions

Management guidance: none published. The only stated milestone is a China launch in 2H2027, plus an ambition to expand Tyemvers globally (press releases, Aug-2026). Consensus growth expectations: n/d (no coverage).

Bull case

  1. China approval re-rates the toxin franchise. A positive NMPA decision (US$1.5M milestone, 5% royalty, 15-year supply) would turn the KRW 45.7B Osong asset from a sunk cost into a cash generator. The plant can scale to 16M vials.

  2. API margins revert to FY2024 levels. FY2024 showed that a 20.9% gross margin and an 11% EBITDA-plus margin are achievable on about KRW 170B of revenue. With a 270-day inventory base, any price stabilisation releases working capital quickly.

  3. Deep asset discount. At about 0.6x book, with land carried at KRW 58.8B and PP&E of KRW 154B against a KRW 74B market cap, the stock prices in persistent losses. Parent support (39% owner) limits tail risk.

Bear case

  1. Structural API price erosion. Indian fermentation leaders (Concord: about 42% EBITDA margin, revenue about 5x CKD Bio's) set the price. CKD Bio's 1H2026 operating loss of KRW 6.7B came despite R&D cuts.

  2. Liquidity squeeze. Cash of KRW 0.6B against KRW 102B of current debt, a current ratio below 1x, and EBITDA/interest of about 1.9x. Any lender retrenchment could force a dilutive equity raise; none has been announced.

  3. Toxin economics are thin. Revenue is about 2% of sales a year after launch, in a market led by Hugel and Nabota. China royalties at 5% would only start in 2H2027, and the US programme is a partner-funded Phase 1.

Key catalysts and monitorables (next 12 months)

Analyst verdict. CKD Bio is a legacy Korean fermentation-API company carrying a growth option it can barely afford. The core business has genuine assets: decades of FDA, AIFA and PMDA approvals, large fermenter volume at Ansan, and CEPs for globally traded molecules such as potassium clavulanate, cyclosporine and acarbose. The FY2024 turnaround (gross margin up from 3% to 21%, operating profit of KRW 11.0B) shows the plant can earn money when pricing cooperates.

The evidence since then is discouraging. Revenue fell 6.8% in FY2025 and a further 2.3% in 1H2026, and operating profit swung to a KRW 6.7B loss in the half, even though R&D spending was cut by more than a quarter from its FY2023 peak. That pattern points to price-driven erosion from Indian and Chinese competitors, not a temporary cost spike.

The balance sheet is now the binding constraint. Net debt of about KRW 146B against TTM EBITDA of about KRW 11B, near-zero cash, and roughly KRW 100B of debt rolling within twelve months leave CKD Bio dependent on lender goodwill and, implicitly, on Chong Kun Dang Holdings.

Tyemvers is a credible, differentiated product: clean-label, halal, non-inferior to Botox in two Phase 3s, and on file in China. But its economics to CKD Bio are modest in the near term. A 5% Chinese royalty and a US$1.5M milestone do not repair the balance sheet before 2028, and domestic sales remain a rounding error against the API base.

At about 0.6x book and about 21x EV/TTM EBITDA, the equity is a leveraged option on API price stabilisation plus China approval. A sustained recovery requires evidence of positive operating cash flow and inventory release in 2H2026. Absent that, the risk of a dilutive recapitalisation or group-level restructuring outweighs the toxin upside.

Stance: Speculative / high-risk. Monitor 3Q2026 results and debt roll-over before taking a constructive view.


Principal sources consulted

  • DART filings via FinancialFilings (FY2025 annual report, 18-Mar-2026), Valueline/DataHero (FY2022–1H2026 line items), Butler and ETFshopping (disclosure lists and preliminary results)

  • S&P Global Market Intelligence via StockAnalysis (FY2018–FY2022)

  • Paasa (FY2021–FY2025 summary financials)

  • CKD Bio corporate website (overview, history, facilities, GMP, R&D pipeline, product catalogues)

  • Korean trade and financial press: Kormedi (Apr-2026, Aug-2026); DailyPharm (2016–2026); Medigate; Medifonews; Dealsite; Bizwatch; BioSpectator; Smart Today; Toyo Economy; FN News; Asia Economy; Hankyung; Medipana

  • NICE D&B / Korea IR Council technical report (Jul-2024); Korea IR Council report (Sep-2022); Hana Financial and Daishin research (2019–2020)

  • Competitor data: Dealsite and Medifonews (Hugel, Medytox, Daewoong); HDFC Sky and ICRA (Concord Biotech); Alphadistill and DailyPharm (Kyongbo)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenurePrior rolesEducationAge

Park Wan-gap (박완갑)

CEO and representative director

Since 28-Mar-2024

Kyongbo Pharmaceutical (group affiliate) from 2010 for 14 years in overseas sales and purchasing; head of API sales from 2022

BS Chemistry and MS Inorganic Chemistry, Hanyang University

—

Lee Jung-jin (이정진)

Former CEO

From 17-Mar-2017; end date n/d (succeeded by Park, Mar-2024)

Head of Daewoong Pharmaceutical's Bio Research Institute; R&D head at Binex; principal researcher at the Osong medical-industry foundation's new-drug centre

PhD Microbiology, Seoul National University

Born 1964

Kang Hee-il (강희일)

Former CEO

Resigned Mar-2017

———

Lee Jung-hee (이정희)

Head of bio division (toxin commercial)

Joined around 2020

Department head for Daewoong's Nabota toxin business

——

Lee Ju-won (이주원)

Former non-executive director of CKD Bio

Dates n/d

Eldest son of group chairman Lee Jang-han; promoted to managing director (상무) at Chong Kun Dang in Jan-2026; holds 2.89% of CKD Holdings

——

Lee Su-han (이수한)

Non-executive director (re-elected Mar-2017)

Current status n/d

———

Kim Young-chan (김영찬)

Outside director (re-elected Mar-2017)

Current status n/d

———

Ahn Dong-myung (안동명)

Standing auditor (re-elected Mar-2017 for 3 years)

Current status n/d

———

Governance Overview

ItemStatusSource

Board size and independence ratio

n/d (CKD Bio's asset size is below the KRW 2T threshold that mandates a majority-independent board)

—

Audit structure

Standing auditor model historically (2017); current structure n/d

DailyPharm (Mar-2017)

Governance report

Corporate governance report filed 1-Jun-2026

Butler disclosure list

Major Shareholders

HolderStake (%)DateSource

Chong Kun Dang Holdings Corp.

39.11

31-Mar-2024

1Q2024 report via NICE D&B

Lee Bok-hwan (relative of chairman Lee Jang-han)

0.05

31-Mar-2024

NICE D&B

Other shareholders

60.84

31-Mar-2024

NICE D&B

Historic: CKD Holdings and affiliates

37.26 / 37.30 / 39.16

Oct-2019 / Feb-2020 / Jun-2022

Hana Securities; Korea IR Council

Foreign ownership (%)

n/d (9.2–9.6% in 2019–2020)

Hana Securities (2019–2020)

—

Treasury shares

02026

Butler

Competitive Landscape

Competitors by Segment

SegmentCompetitorCountryLatest revenue (as reported)Positioning vs CKD BioSource

Fermentation immunosuppressant APIs

Concord Biotech

India

FY2025 (Mar-25) revenue INR 1,200.1 crore; API INR 940.1 crore; EBITDA INR 506.3 crore (42.2% margin)

Scale and cost leader; claims to be the only supplier of a complete fermentation immunosuppressant API portfolio

HDFC Sky; Concord earnings call

Immunosuppressant / statin APIs

Biocon

India

—

Large-scale fermentation API competitor

—

Rifampicin / anti-TB APIs

Lupin and Chinese producers

India / China

—

Low-cost anti-TB supply

—

Clavulanate / β-lactam APIs

Sandoz (Kundl) and Chinese clavulanate producers

Austria / China

—

Integrated β-lactam chains

—

Korean APIs (group affiliate)

Kyongbo Pharmaceutical

Korea

2025 revenue KRW 264.1B, operating margin 1.3%; API segment KRW 101.1B (Alphadistill) or KRW 133.8B (DailyPharm) — sources conflict

Synthetic cephalosporin and oncology APIs plus finished products; building ADC CDMO

Alphadistill; DailyPharm (May-2026)

Korean APIs

Yuhan Chemical; Hanmi Fine Chemical; ST Pharm

Korea

n/d (ST Pharm 3Q25 revenue KRW 81.9B)

Captive or CDMO-oriented API houses

Medigate (Nov-2025)

Botulinum toxin

Hugel

Korea

2025 revenue KRW 425.1B; OI KRW 201.6B; toxin KRW 233.8B

Korean market leader; US, China and EU approvals

Dealsite (Feb-2026)

Botulinum toxin

Daewoong Pharmaceutical (Nabota/Jeuveau)

Korea

Nabota 2025 sales KRW 229.0B

US partner Evolus; about 14% US aesthetic share (2025)

Kormedi (2026); Bizwatch (Jul-2025)

Botulinum toxin

Medytox

Korea

2025 revenue KRW 247.3B; OI KRW 17.2B

Premium Coretox, Newlux; also entering probiotics

Medifonews (2026)

Botulinum toxin

AbbVie (Botox), Ipsen (Dysport), Merz (Xeomin), Huons BioPharma, Jetema

US / FR / DE / KR

—

Global incumbents and domestic challengers

—

Probiotics

Cell Biotech; Novonesis (Chr. Hansen); IFF; Medytox (MT961)

KR / DK / US

—

Branded strain owners and global ingredient majors

—

Peer Comparison FY2025

MetricCKD Bio (FY2025)Hugel (FY2025)Concord Biotech (FY2025, Mar-25)Kyongbo Pharm. (FY2025)

Revenue

KRW 160.1B

KRW 425.1B

INR 1,200.1 crore

KRW 264.1B

Revenue growth YoY

-6.8%+14.0%+18.0%+10.7%

Operating margin

2.2%47.4%

n/d (EBITDA margin 42.2%)

1.3%

R&D intensity

7.9%——

6.9% (DailyPharm, reported period)

Export share

≈72–79%

Toxin and filler export share 74%

45% exports (domestic 55%)

—

Recent Developments

Litigation, regulatory actions, layoffs and hiring in this period:* none material identified. Headcount was 530 at 31-Mar-2026.

Company Snapshot

$112.7M

Revenue

530

Employees

2001

Founded

SWOT Analysis

Strengths

  • A multi-jurisdiction GMP estate (US FDA, AIFA, PMDA, TGA, WHO, ANVISA, COFEPRIS) and CEPs for clavulanate, cyclosporine, acarbose, rifamycin and teicoplanin create regulatory switching costs for customers (company GMP and history pages).
  • Large-scale fermentation infrastructure: Ansan Buildings A and B alone exceed 1,500 m³ of fermenter volume (facility page).
  • Toxin differentiation: HSA-free vegan formulation, a GenBank-registered strain, and the first halal-certified toxin (BPJPH, May-2025).
  • Clinical validation of Tyemvers: non-inferiority to Botox in a 300-patient Korean Phase 3 and a 554-patient Chinese Phase 3 (BioSpectator, Jul-2025; Bizwatch, Aug-2026).
  • Group backing: Chong Kun Dang Holdings owns 39.11%, and debt roll-over to KRW 146B of borrowings has continued despite losses (NICE D&B; Valueline).
  • A demonstrated cost-out capability: FY2024 gross margin rose to 20.9% from 3.1% while revenue grew 7.1% (Paasa/DART).

Weaknesses

  • Concentration: APIs are 84–86% of revenue and antibiotics 62% (1Q2025, 2Q2026).
  • Leverage and liquidity: net debt of KRW 141.4B against equity of KRW 127.0B (FY2025); current ratio of 0.90x; cash of KRW 0.6B at Jun-2026 (Valueline).
  • Persistent negative operating cash flow in four of five years, with an inventory build to KRW 96.8B and a cash conversion cycle of 331 days (FY2025).
  • Low returns: ROIC of at most about 4% in every year from FY2021 to FY2025 (computed).
  • Sub-scale against Indian peers: Concord Biotech's revenue is about 5x CKD Bio's, with a 42% EBITDA margin.
  • Thin disclosure (no guidance, no segment profit), which limits investor visibility; there is no analyst coverage (Simply Wall St).

Opportunities

  • China toxin approval: US$1.5M milestone plus 5% royalty and a 15-year supply agreement; launch targeted for 2H2027 (Kormedi, Aug-2026).
  • Neuropsychiatric indications via Healis (US Phase 1 in MDD), building on Allergan's earlier Phase 2 signal at 30U (BioSpectator, Jul-2026).
  • Halal markets: Indonesia, the Middle East and Malaysia, with an addressable Muslim population of about 2 billion (company release, May-2025).
  • Osong capacity headroom (6M to 16M vials) for contract toxin or export supply (DailyPharm, 2022).
  • Immunosuppressant end-market growth (tacrolimus >10% a year in Korea since 2023) and new APIs (diquafosol, an antiviral, an anti-ulcer agent) (DailyPharm, Aug-2025; pipeline).
  • Microbiome CDMO and functional probiotic ingredients (CKDB-305 launched; CKDB-315 human study complete).

Threats

  • Indian and Chinese API price competition already eroding margins (operating margin of -4.2% in 1Q2026) (Kormedi; Nate).
  • Crowded toxin market: Hugel (KRW 233.8B toxin sales), Nabota (KRW 229.0B) and Medytox dominate domestically and in export markets.
  • Refinancing and interest-rate risk: KRW 102B of current debt at Jun-2026 against about KRW 10.6B of TTM EBITDA.
  • FX risk: exports of about 72–79% of revenue make results sensitive to KRW strength.
  • Related-party dependence in probiotics; analysts have flagged lower Chong Kun Dang Health OEM volumes since 2022 (Korea IR Council).
  • NMPA review timing and Cutia's commercial execution are outside CKD Bio's control.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
01-Apr-2025MFDS approval of Tyemvers 100U (approved 31-Mar) disclosed; shares rose about 5% intraday to KRW 20,900 Asia Economy; DailyPharmCompany becomes Korea's 6th domestic toxin maker
Apr-2025US FDA IND clearance and Phase 1 initiation reported Toyo Economy (Jul-2025)North American regulatory pathway opened
25-Apr-20251Q2025 preliminary results: revenue KRW 42.5B (-6.6%), OI KRW 2.1B (-34.5%), NI KRW 0.9B DART via ETFshoppingMargin compression begins
13/14-May-2025First halal certificate for a botulinum toxin (Indonesia BPJPH) Smart Today; Toyo EconomyDifferentiation for Muslim-majority markets
Jun-2025Export share 79.0% in 1Q2025, among the highest of 50 listed Korean pharma companies Medigate (Jun-2025)Confirms FX and price-competition exposure
Late Jun-2025Korean Phase 3 published in *Journal of Cosmetic Dermatology* BioSpectator (Jul-2025)Scientific validation for marketing
21/22-Jul-2025Tyemvers launched in Korea; initial batches allocated (Apr disclosure) Medigate; Toyo EconomyFirst toxin product revenue
25-Jul-20252Q2025 preliminary results: revenue KRW 41.2B (-19.1%), OI KRW 2.9B (-42.3%), NI KRW -0.5B DART via ETFshoppingSharp YoY decline against a strong 2Q2024
Aug-2025Trade press features the dedicated toxin sales organisation and a domestic-first strategy Dealsite (Aug-2025)Commercial set-up
31-Oct-20253Q2025 preliminary results: revenue KRW 34.1B (-22.3%), OI KRW -1.5B, NI KRW -2.2B DART via ETFshoppingReturn to quarterly losses
Jan-2026China Phase 3 clinical study report received: non-inferior to Botox Kormedi (Apr-2026)De-risks the China filing
Jan-2026Lee Ju-won (former CKD Bio non-executive director, owner's son) promoted at Chong Kun Dang Dealsite (Jan-2026)Group succession context
Early 2026FY2025 preliminary results: revenue KRW 160.1B (-6.8%), OI KRW 3.6B (-67%), NI KRW -2.9B Kormedi; ButlerTurnaround partially reversed
26/27-Feb-2026AGM notice for 26-Mar-2026 at the Osong plant Simply Wall StGovernance calendar
18-Mar-2026FY2025 annual report filed: total assets KRW 299.87B; equity KRW 127.04B; OCF KRW -4.14B FinancialFilingsBalance-sheet deterioration confirmed
26-Mar-2026AGM held (resolutions n/d) Simply Wall St—
24-Apr-20261Q2026 preliminary results: revenue KRW 40.7B (-4.3%), OI KRW -1.7B, NI KRW -2.0B Nate/Bio report; KormediOperating margin falls to -4.2%
27-Apr-2026Press analysis attributes the profit fall to Indian and Chinese API price competition KormediStructural headwind identified
01-Jun-2026Corporate governance report filed ButlerDisclosure compliance
11-Jun-2026Tyemvers 1st-anniversary symposium in Seoul; 200U unveiled for August FN News (Jul-2026)Market-building
26-Jun-2026Sustainability report filed ButlerESG disclosure
29-Jul-2026Share price at KRW 12,300; 52-week range KRW 12,150–27,650; 1-year change about -49% Investing.comMarket loss of confidence
30/31-Jul-2026FDA clears Phase 1 IND for Tyemvers in major depressive disorder (Healis-run) DailyPharm; Dealsite; BioSpectatorLow-cost therapeutic option
31-Jul-20262Q2026 preliminary results: revenue KRW 41.1B (-0.3%), OI KRW -5.0B, NI KRW -5.4B; 1H OI KRW -6.7B Kormedi (Aug-2026)Losses widen
Early Aug-2026Tyemvers 200U launch (planned) Medifonews (Jul-2026)Line extension
14-Aug-2026—
18-Aug-2026China NMPA BLA for CU-20101 submitted; 2H2027 launch target; US$1.5M approval milestone; 5% royalty Bizwatch; Medigate; KormediKey 12–24-month catalyst
1H2026KRW 37.0B bond redeemed; KRW 30B new long-term borrowing; short-term borrowings up to KRW 96.3B Valueline (DART)Refinancing dependence
Sep-2026Share price near a 52-week low of about KRW 11,770 StockhubValuation at about 0.55–0.6x book

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total revenue rose from KRW 124.6 Bn in FY2020 to KRW 156 Bn in FY2022.
CKD Bio Corp. — Revenue by Segment
Series (KRW Bn)FY2020FY2021FY2022
Total revenue124.6142.2156
API division revenue109.2108.2125.1
Probiotics division revenue15.43425
Botulinum toxin division revenue006

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.